# PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

> **NCT00491998** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vernalis (R&D) Ltd** · enrollment: 27 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** V1512
- **DRUG:** V1512
- **DRUG:** V1512 and Entacapone

## Key facts

- **NCT ID:** NCT00491998
- **Lead sponsor:** Vernalis (R&D) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2011-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00491998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00491998, "PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00491998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*